Bristol-Myers Squibb's (BMY) 'Disappointing' Opdivo Data in NSCLC has No Impact on Ratings - Moody's

Moody's Investors Service commented that Bristol-Myers Squibb's (NYSE: BMY) disappointing clinical trial result for Opdivo in first-line lung cancer is a setback because this indication represented a sizeable growth opportunity. There is no impact on Bristol's A2/Prime-1 ratings or stable rating outlook.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) call put ratio 6.8 calls to 1 put with a focus on spreader of 8244 contracts of June and July 57.50 calls
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$231 at Bernstein SocGen
• Hilton Grand Vacations completes $300 million securitization